Follow the Oryzon Genomics, S.A. stock price and the full directors' dealings record of the company, a listed issuer based in Spain. Shares trade on the ES market, under the oversight of CNMV. Operating in the Health Care sector, Oryzon Genomics, S.A. has logged 8 reports. Market capitalisation: €244.7m. The latest transaction was reported on 8 February 2024 (Other). Among the most active insiders: DOUGLAS FALLER. Every trade is accessible without an account.
8
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€84,870
1 ops.
Sell Volume
36Σ signal
Buys n/a€84,870 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
10,000 shares@ €2.61100.0% of flowShareXOOFISINISIN ES0167733015CNMV:2022092563
8 of 8 declarations
About Oryzon Genomics, S.A.
Oryzon Genomics, S.A. is a biopharmaceutical company focused on developing innovative therapies for the treatment of neurodegenerative diseases and cancers. It is listed on the XMAD market.